ASCO 2023 | PSMA-TRT, 225Ac-J591 and 177Lu-PSMA I&T in mCRPC

“Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, provides an overview of a Phase I trial (NCT04886986) of PSMA-targeted radionuclide therapy, 225Ac-J591, an alpha-radiolabeled antibody, and 177Lu-PSMA I&T, a beta-radioligand, in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients followed a similar dosing regiment found in the Phase III SPLASH trial (NCT04647526) and only two cases of dose-limiting toxicities were reported. The combination therapy was overall found to be feasible and tolerable. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.